Austar Lifesciences's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 72.7.
Austar Lifesciences's Days Inventory for the
six
months ended in Dec. 2025 was 64.4.
Austar Lifesciences's Days Payable for the
six
months ended in Dec. 2025 was 110.39.
Therefore, Austar Lifesciences's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 26.71.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Austar Lifesciences Cash Conversion Cycle Related Terms
Austar Lifesciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AULSF vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Austar Lifesciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Austar Lifesciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a Cash Conversion Cycle of 26.71 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Austar Lifesciences and its competitors.
Is Austar Lifesciences' Cash Conversion Cycle too high?
Austar Lifesciences' current Cash Conversion Cycle is 26.71. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. Austar Lifesciences' value of 26.71 is 83% below this industry median. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Cash Conversion Cycle compare to ABT and SYK?
Austar Lifesciences' Cash Conversion Cycle of 26.71 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. Austar Lifesciences' value of 26.71 is 83% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current Cash Conversion Cycle of 26.71 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current Cash Conversion Cycle is 26.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current Cash Conversion Cycle of 26.71. The stock's GF Value™ is $0.10, compared to a current price of $0.02 — trading 80% below its estimated fair value. The current Cash Conversion Cycle is 26.71 and 83% below the Medical Devices & Instruments industry median of 156.96. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current Cash Conversion Cycle is 26.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 80% below its estimated GF Value™ of $0.10.
Key valuation signals for AULSF:
Cash Conversion Cycle: 26.71
GF Value™: $0.10 vs. price of $0.02 (80% below fair value)
Industry Position: 83% below the Medical Devices & Instruments median
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
